跳至主要内容
临床试验/NCT02764658
NCT02764658Unknown不适用

Studies in Pulmonary Inflammation and the Effectiveness of Pulmonary Recovery in COPD Patients:the Mechanism of Proteoglycan 4

Taipei Medical University0 个研究点目标入组 90 人开始时间: 2016年5月最近更新:
适应症

试验速览

阶段
不适用
入组人数
90
主要终点
The systemic inflamation biomakers

研究概览

简要总结

The investigators previous research has demonstrated that proteoglycan 4 (PRG4) may be a biomarker for identification of severity in COPD. PRG4 was more sensitive and specific than CRP for confirming COPD severity and acute exacerbation frequency. It was related to the 1-year force vital capacity decline in COPD patients. The past study found that Prg4 is an immunomodulatory factor regulating parathyroid hormone actions on hematopoietic cells in mice. Previous report showed that voluntary wheel running and fluid flow shear stress that promote the expression of the Prg4 and association with pulmonary inflammation. COPD patients are characterized by a progressive decrease of lung function that is associated with increased in the airway and systemic inflammation. Pulmonary recovery (PR) is able to decrease acute exacerbation, maintain pulmonary function, increase exercise tolerance and improve quality of life in COPD patients, but it is unknown the mechanism of PRG4. The current study aimed to study in the pulmonary inflammation and the effectiveness of pulmonary recovery in COPD Patients:The mechanism of PRG 4.

详细描述

The investigators previous research has demonstrated that proteoglycan 4 (PRG4) may be a biomarker for identification of severity in COPD. PRG4 was more sensitive and specific than CRP for confirming COPD severity and acute exacerbation frequency. It was related to the 1-year force vital capacity decline in COPD patients. The past study found that Prg4 is an immunomodulatory factor regulating parathyroid hormone actions on hematopoietic cells in mice. Previous report showed that voluntary wheel running and fluid flow shear stress that promote the expression of the Prg4 and association with pulmonary inflammation. COPD patients are characterized by a progressive decrease of lung function that is associated with increased in the airway and systemic inflammation. Pulmonary recovery (PR) is able to decrease acute exacerbation, maintain pulmonary function, increase exercise tolerance and improve quality of life in COPD patients, but it is unknown the mechanism of PRG4. The current study aimed to study in the pulmonary inflammation and the effectiveness of pulmonary recovery in COPD Patients:The mechanism of PRG 4.

  1. Proteoglycan 4 is correlated with pulmonary inflammation and decline of pulmonary function in the different phenotype of COPD.

1-1 Classification of characteristic、the severity of disease、pulmonary functional test、exercise capacity and blood sample collection for routine analysis.

1-2 Human blood bio-bank and molecular analysis: PRG4、IL-6、IL-8、TNFα、CRP& IL-10.

1-3 To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in COPD patients. 2. The mechanism of PRG 4 in the effectiveness of PR on the AECOPD. 2-1 The PR program: The combination effect of negative pressure ventilation and exercise training program on acute exacerbation of COPD (AECOPD).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
Double (Participant, Investigator)

入排标准

年龄范围
40 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Hospitalized patients with acute exacerbation of COPD
  • GOLD diagnostic criteria based on the COPD, the use of inhaled bronchodilators: the first second forced expiratory volume (FEV1.0) / forced vital capacity (FVC) <70%.
  • Age ≧ 40 and ≦ 80 years old, is currently not accepting any research project.
  • Physician assess the patient is currently in stable condition vital signs, complain dyspnea of exercise, consult RT for pulmonary rehabilitation.
  • The purpose of this study by researchers explain, the researchers agreed to participate in this.
  • Stable COPD outpatients
  • GOLD diagnostic criteria based on the COPD, the use of inhaled bronchodilators: the first second forced expiratory volume (FEV1.0) / forced vital capacity (FVC) <70%.
  • Age ≧ 40 and ≦ 80 years old, is currently not accepting any research project.
  • The purpose of this study by researchers explain, the researchers agreed to participate in this.

排除标准

  • Hospitalized patients with acute exacerbation of COPD
  • Unstable vital signs: blood pressure <90 mm Hg, blood oxygen levels (SpO2) at Tx under still <85%.
  • Associated with neuromuscular function disorders such as hemiplegia or no independent walking function.
  • Have been diagnosed with severe mental disorders, such as dementia or or unable to cooperating people.
  • Stable COPD outpatients
  • Over the past three months there have been acute infection or are in a state of acute attacks.
  • Associated with neuromuscular function disorders such as hemiplegia or no independent walking function.
  • Have been diagnosed with severe mental disorders, such as dementia or unable to cooperating people

结局指标

主要结局

The systemic inflamation biomakers

时间窗: 0~12 months

Measured the proteaglycan4、IL-6、IL-8、TNFα、CRP\& IL-10 from the supernatant with COPD patients

次要结局

  • Exercise capacity(0~12 months)
  • The correlaton with the exercise capacity and systemic inflammationcytokines(0~12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shu-Chuan Ho

School of Respiratory Therapy

Taipei Medical University

相似试验